Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-28, Stock:NVS, The news for the past five days is as follows:
2019-03-21: NEWS1: Is Biogen a Bad-News Buy Now?.NEWS2: Cooper Companies' (COO) CooperVision Gains Momentum Globally.NEWS3: Cooper Companies' (COO) CooperVision Gains Momentum Globally.NEWS4: Cooper Companies' (COO) CooperVision Gains Momentum Globally.
2019-03-22: NEWS1: Conatus (CNAT) Declines on Failure of NASH Fibrosis Study.NEWS2: Biogen Stock Crashes on Termination of Alzheimer's Studies.NEWS3: Biogen Stock Crashes on Termination of Alzheimer's Studies.NEWS4: Biogen Stock Crashes on Termination of Alzheimer's Studies.NEWS5: Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo.NEWS6: Novartis says listing of Alcon eye care business expected on April 9.NEWS7: Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook.
2019-03-25: NEWS1: Were Hedge Funds Right About Novartis AG  (NVS)?.NEWS2: Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more.NEWS3: Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook.
2019-03-26: NEWS1: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs.
2019-03-27: NEWS1: Novartis (NVS) Receives FDA Approval for MS Drug Mayzent.NEWS2: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS3: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS4: Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study.NEWS5: The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval.NEWS6: Novartis MS drug wins FDA's blessing amid scrutiny of $88k annual price.NEWS7: 6 Gene Therapy M&A Targets On The Radar.NEWS8: Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod.NEWS9: FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis.NEWS10: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO.NEWS11: Novartis new MS drug Mayzent to be priced at $88,000 per year.NEWS12: Novartis gets U.S. approval for new drug to treat multiple sclerosis.

Answer: Rise